Medical Cannabis and Quality of Life: What a Small Appalachian Survey Found
A small 2024 survey of adults in rural Virginia found that patients using medical cannabis for anxiety, depression, insomnia, or chronic pain reported lower prescription-medication use and improvements in symptoms, general health, and quality of life. The findings are encouraging, but the study’s design cannot establish that cannabis caused those improvements.
The study, published in The Journal for Nurse Practitioners, surveyed 31 adults receiving care at a medical cannabis clinic in Virginia’s Appalachian region. Researchers examined participants’ prescription-medication use, perceived health, quality of life, symptom severity, knowledge of cannabis, and beliefs about its medical use.
Participants completed an online survey asking them to compare their experiences before and after adding medical cannabis to their treatment regimen. About 28% said their general health had improved, while 57% reported a better quality of life. In addition, 59% reported less severe anxiety and 53% reported less severe insomnia after beginning medical cannabis. Prescription-medication use also declined significantly in the study’s before-and-after comparisons.
Open-ended responses reflected those survey results. Participants described better sleep, fewer panic attacks, less depression and anxiety, and relief from nausea or chronic pain. Some said cannabis had helped them reduce or stop using narcotic medications. These accounts provide context for the numerical findings, but they are subjective reports rather than clinical measurements.
What the study can—and cannot—show
The researchers did not conduct a randomized clinical trial. All participants were already using medical cannabis, and there was no comparison group of similar patients who did not use it. The sample was also small and drawn from a single clinic. As a result, the study may reflect selection and recall bias: people who experienced benefits may have been more likely to participate or to report them. Changes in other treatments, health conditions, or expectations could also have influenced the results.
For those reasons, the findings show an association between medical-cannabis use and participants’ reported outcomes—not proof that cannabis treated depression, anxiety, insomnia, or chronic pain. Broader evidence remains mixed. The National Center for Complementary and Integrative Health says cannabis and cannabinoid products may provide modest short-term benefits for some types of chronic pain, while evidence for anxiety and sleep problems remains limited or uncertain.
Why the Appalachian setting matters
The study’s authors argue that access and provider education deserve particular attention in Appalachia, where rural residents may face financial, geographic, and healthcare barriers. The Appalachian Regional Commission’s data show that the region’s median household income remains below the national level. An ARC analysis also found that, in 2021, the Appalachian Region’s mortality rate from so-called diseases of despair—including overdose, suicide, and liver disease or cirrhosis—was 43% higher than in the non-Appalachian United States.
Within the survey, nurse practitioners were the most commonly cited source of information about medical cannabis, followed by family members and physicians. The authors say better training could help healthcare professionals discuss possible benefits, side effects, drug interactions, and legal restrictions more confidently. In Virginia and other states, medical cannabis is accessed under state-specific rules; it is not a conventional prescription medication.
Medical cannabis also carries risks. The Centers for Disease Control and Prevention warns that some users develop cannabis use disorder, with risk increasing among people who use cannabis frequently or begin at a younger age. Cannabis can also cause impairment, and products with high concentrations of THC may increase the risk of overconsumption and adverse effects.
The Virginia survey adds patient-reported evidence from an underserved rural population, but it should be viewed as an early observational study rather than definitive proof of efficacy. Larger studies—with objective health measures, longer follow-up, and appropriate comparison groups—are needed to determine which patients may benefit, which products and doses are safest, and whether cannabis can reduce reliance on other medications without creating new harms.
